Kaken Pharmaceutical Co., Ltd.
Financial Summary for the Six Months Ended March 2027 (Interim) [Japan GAAP] (Consolidated)
Net sales were 48,957 million yen, up 24.4% year-over-year. Operating income was 10,164 million yen, ordinary income was 10,708 million yen, and net income attributable to owners of parent for the interim period was 8,000 million yen, a substantial increase. Full-year outlook is net sales of 89,900 million yen and net income of 6,500 million yen. The increase was mainly driven by higher milestone income.
Key Figures
- Net sales: 48,957 million yen (Up 24.4% Year-over-Year)
- Net income attributable to owners of parent: 8,000 million yen (Up 698.1% Year-over-Year)
- Research and development expenses: 9,943 million yen (Down 14.8% Year-over-Year)
AI要約
Overview of Performance
Kaken Pharmaceutical achieved significant increases in the interim period driven mainly by higher milestone income received in the past. Net sales were 48,957 million yen, up 24.4% YoY; operating income was 10,164 million yen; ordinary income was 10,708 million yen; and net income attributable to owners of parent for the interim period was 8,000 million yen. Research and development expenses decreased 14.8% to 9,943 million yen, which together with contributions from milestone income supported improvements in operating and ordinary income.
Outlook and Key Considerations
Full-year forecast: net sales 89,900 million yen, operating income 7,900 million yen, ordinary income 8,600 million yen, and net income attributable to owners of parent 6,500 million yen. Revenue and profit growth are expected due to one-time receipts from milestone achievements; however, attention should be paid to the underlying market environment, progress of clinical development, and the sustainability of license income.
Kaken Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
